Endometrial Cancer: Awareness and Equity

CE / CME

Improving Provider Awareness About Healthcare Equity: Improving All Patients’ Access to Care in Endometrial Cancer

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 15, 2023

Expiration: June 14, 2024

Shannon N. Westin
Shannon N. Westin, MD, MPH, FASCO

Activity

Progress
1
Course Completed

References

  1. National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: uterine cancer. seer.cancer.gov/statfacts/html/corp.html. Accessed March 28, 2023. 
  2. Chapman-Davis E, Webster EM, Balogun OD, et al. Landmark series on disparities: uterine cancer and strategies for mitigation. Ann Surg Oncol. 2023;30:48-57.
  3. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014;15:e268-e278.
  4. Doll KM, Khor S, Odem-Davis K, et al. Role of bleeding recognition and evaluation in Black-White disparities in endometrial cancer. Am J Obstet Gynecol. 2018;219:593.e1-593.e14.
  5. Romano SS, Doll KM. The impact of fibroids and histologic subtype on the performance of US clinical guidelines for the diagnosis of endometrial cancer among Black women. Ethn Dis. 2020;30:543-552.
  6. American Cancer Society. Cancer Facts & Figures 2021. American Cancer Society; 2021.
  7. Maxwell GL, Risinger JI, Hayes KA, et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res. 2000;6:2999-3005.
  8. Francies FZ, Marima R, Hull R, et al. Genomics and splicing events of type II endometrial cancers in the black population: racial disparity, socioeconomic and geographical differences. Am J Cancer Res. 2020;10:3061-3082.
  9. Kohler MF, Carney P, Dodge R, et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol. 1996;175:1246-1252.
  10. Clifford SL, Kaminetsky CP, Cirisano FD, et al. Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Am J Obstet Gynecol. 1997;176:S229-S232.
  11. US Centers for Disease Control and Prevention. Gynecologic Cancer Incidence, United States—2012-2016. US Centers for Disease Control and Prevention; 2019. 
  12. Henley SJ, Miller JW, Dowling NF, et al. Uterine cancer incidence and mortality - United States, 1999-2016. MMWR Morb Mortal Wkly Rep. 2018;67:1333-1338.
  13. Rauh-Hain JA, Buskwofie A, Clemmer J, et al. Racial disparities in treatment of high-grade endometrial cancer in the Medicare population. Obstet Gynecol. 2015;125:843-851.
  14. Wright JD, Fiorelli J, Schiff PB, et al. Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time. Cancer. 2009;115:1276-1285.
  15. Long B, Liu FW, Bristow RE. Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States. Gynecol Oncol. 2013;130:652-659.
  16. Mukerji B, Baptiste C, Chen L, et al. Racial disparities in young women with endometrial cancer. Gynecol Oncol. 2018;148:527-534.
  17. Doll KM, Snyder CR, Ford CL. Endometrial cancer disparities: a race-conscious critique of the literature. Am J Obstet Gynecol. 2018;218:474-482.e2.
  18. Bregar AJ, Alejandro Rauh-Hain J, Spencer R, et al. Disparities in receipt of care for high-grade endometrial cancer: a National Cancer Data Base analysis. Gynecol Oncol. 2017;145:114-121.
  19. Sud S, Holmes J, Eblan M, et al. Clinical characteristics associated with racial disparities in endometrial cancer outcomes: a surveillance, epidemiology and end results analysis. Gynecol Oncol. 2018;148:349-356.
  20. Buskwofie A, Huang Y, Tergas AI, et al. Impact of hospital volume on racial disparities and outcomes for endometrial cancer. Gynecol Oncol. 2018;149:329-336.
  21. Wright JD, Lewin SN, Deutsch I, et al. Effect of surgical volume on morbidity and mortality of abdominal hysterectomy for endometrial cancer. Obstet Gynecol. 2011;117:1051-1059.
  22. MacKay HJ, Levine DA, Bae-Jump VL, et al. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget. 2017;8:84579-84594.
  23. León-Castillo A, de Boer SM, Powell ME, et al; TransPORTEC consortium. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38:3388-3397.
  24. ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol. 2014;124:1042-1054. 
  25. Cho KR, Cooper K, Croce S, et al. International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: guidelines from the Special Techniques and Ancillary Studies Group. Int J Gynecol Pathol. 2019;38(suppl 1):S114-S122.
  26. Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31:12-39.
  27. Crosbie EJ, Ryan NAJ, Arends MJ, et al; Manchester International Consensus Group. The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genet Med. 2019;21:2390-2400.
  28. Ryan NAJ, Glaire MA, Blake D, et al. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med. 2019;21:2167-2180.
  29. Takeda T, Banno K, Yanokura M, et al. Methylation analysis of DNA mismatch repair genes using DNA derived from the peripheral blood of patients with endometrial cancer: epimutation in endometrial carcinogenesis. Genes (Basel). 2016;7:86.
  30. Richman S. Deficient mismatch repair: Read all about it (Review). Int J Oncol. 2015;47:1189-1202.
  31. Buza N. HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand. Arch Pathol Lab Med. 2021;145:687-691.
  32. Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002): updated overall survival analysis. Clin Cancer Res. 2020;26:3928-3935.
  33. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: uterine neoplasms. v.2.2023. nccn.org. Accessed June 6, 2023.
  34. American Cancer Society. Treatment choices for endometrial cancer, by stage. cancer.org/cancer/endometrial-cancer/treating/by-stage.html. Accessed March 28, 2023.
  35. Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38:3841-3850.
  36. Huang AB, Huang Y, Hur C, et al. Impact of quality of care on racial disparities in survival for endometrial cancer. Am J Obstet Gynecol. 2020;223:396.e1-396.e13.
  37. O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40:752-761.
  38. Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10:e003777.
  39. Makker V, Colombo N, Casado Herráez A, et al; Study 309–KEYNOTE-775 Investigators. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386:437-448.
  40. Mirza M, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Eng J Med. 2023;[Epub].
  41. Eskander R, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Eng J Med. 2023;[Epub].
  42. Vergote I, Pérez Fidalgo A, Hamilton E, et al. SIENDO/ENGOT-EN5/GOG-3055: a randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer. Presented at: 2022 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer; March 18-21, 2022. Abstract 249.
  43. Scalici J, Laughlin DD, Finan MA, et al. The trend towards minimally invasive surgery (MIS) for endometrial cancer: an ACS-NSQIP evaluation of surgical outcomes. Gynecol Oncol 2015;136:512-515.
  44. Igwe E, Woodburn J, Davolos J, et al. Patient perceptions and willingness to participate in clinical trials. Gynecol Oncol. 2016;142:520-524. 
  45. Durant RW, Wenzel JA, Scarinci IC, et al. Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: enhancing minority participation in clinical trials (EMPaCT). Cancer. 2014;12:1097-1105.
  46. Pozzar RA, Berry DL. Patient-centered research priorities in ovarian cancer: A systematic review of potential determinants of guideline care. Gynecol Oncol. 2017;147:714-722. 
  47. Patel SN, Staples JN, Garcia C, et al. Are ethnic and racial minority women less likely to participate in clinical trials? Gynecol Oncol. 2020;157:323-328.
  48. Nyakudarika NC, Holschneider CH, Sinno AK. Universal social needs assessment in gynecologic oncology: An important step toward more informed and targeted care in the public safety net. Cancer. 2021;127:3809-3816. 
  49. Esnaola NR. A blueprint for addressing cancer disparities. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Oral presentation. 
  50. Chatterjee S, Gupta D, Caputo TA, et al. Disparities in gynecological malignancies. Front Oncol. 2016;6:36.